Alto Neuroscience Files 8-K Report

TL;DR

Alto Neuroscience filed an 8-K. Check for updates.

AI Summary

On October 22, 2024, Alto Neuroscience, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific financial figures or significant business events were detailed in the provided excerpt.

Why It Matters

This filing indicates that Alto Neuroscience, Inc. is making a regulatory submission to the SEC, which could contain important updates for investors.

Risk Assessment

Risk Level: low — The provided excerpt is a standard SEC filing notification and does not contain information that inherently poses a high risk.

Key Players & Entities

• Alto Neuroscience, Inc. (company) — Registrant
• October 22, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• 001-41944 (identifier) — SEC File Number
• 650 Castro Street, Suite 450, Mountain View, CA 94041 (address) — Principal executive offices

FAQ

From the Filing

0001193125-24-241092.txt : 20241022 0001193125-24-241092.hdr.sgml : 20241022 20241022163500 ACCESSION NUMBER: 0001193125-24-241092 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20241022 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241022 DATE AS OF CHANGE: 20241022 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Alto Neuroscience, Inc. CENTRAL INDEX KEY: 0001999480 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 834210124 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41944 FILM NUMBER: 241386708 BUSINESS ADDRESS: STREET 1: 650 CASTRO STREET, SUITE 450 CITY: MOUNTAIN VIEW STATE: CA ZIP: 94041 BUSINESS PHONE: 773-255-5012 MAIL ADDRESS: STREET 1: 650 CASTRO STREET, SUITE 450 CITY: MOUNTAIN VIEW STATE: CA ZIP: 94041 8-K 1 d876702d8k.htm 8-K 8-K false 0001999480 0001999480 2024-10-22 2024-10-22     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2024     ALTO NEUROSCIENCE, INC. (Exact Name of Registrant as Specified in its Charter)       Delaware   001-41944   83-4210124 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)   650 Castro Street , Suite 450 , Mountain View , CA   94041 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code: (650) 200-0412 N/A (Former name or former address, if changed since last report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.0001 par value per share   ANRO   New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company  ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐       Item 8.01 Other Events. On October 22, 2024, Alto Neuroscience, Inc. (the “Company”) issued a press release entitled “Alto Neuroscience Reports Topline Results from a Phase 2b Trial Evaluating ALTO-100 as a Treatment for Major Depressive Disorder,” in which the Company reported that its Phase 2b study of ALTO-100 in patients with major depressive disorder did not meet its primary endpoint, assessed by a change from baseline in Montgomery-Åsberg Depression Rating Scale, compared to placebo. The Company further reported that the favorable safety and tolerability profile of ALTO-100 was consistent with previously reported studies. A copy